JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.3
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 14, Issue 2 (2022)
Iran J War Public Health 2022, 14(2): 221-224 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2021/09/5 | Accepted: 2022/04/23 | Published: 2022/05/30
Received: 2021/09/5 | Accepted: 2022/04/23 | Published: 2022/05/30
How to cite this article
AL-Kinani B, AL-Mashhedy L. The Association between Adiponectin, Adiponectin Receptor, and Obesity for Diabetic Female Type II. Iran J War Public Health 2022; 14 (2) :221-224
URL: http://ijwph.ir/article-1-1015-en.html
URL: http://ijwph.ir/article-1-1015-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
B.H. AL-Kinani *1, L.A. AL-Mashhedy1
1- Department of Chemistry, College of Science, University of Babylon, Hilla, Iraq
Abstract (806 Views)
Aims: Adiponectin is associated with obesity and unregulated diabetes, although it may be useful considering the consequences of glycemic control and obesity on Adiponectin. This study investigated the association between Adiponectin, Adiponectin Receptor, and Obesity for Diabetic Female Type II.
Material & Methods: In this research, 54 female patients with type 2 diabetes and 36 non-diabetics participated, individuals from two groups, obese and non-obese, compared with apparently healthy control. The Adiponectin and Adiponectin receptor were measured by ELISA sandwich and Colorimetric methods were used for calculating fasting blood glucose. Blood samples were collected and drawn (5 ml) for each individual. For statistical analysis, SPSS 26.0 by ANOVA and Pearson's correlation coefficients were used.
Findings: Adiponectin and the Adiponectin receptor were measured, and the values of both were decreased in patients with type 2 diabetes who have the highest FBG, and also decreased for obese females, which have the highest BMI, where the positive significant values were observed when correlated body mass index (r=-0.57, p=0.001), and fasting blood glucose (r=0.291, p=0.0.06), while a negative correlated observed between Adiponectin receptor (r=-0.59, p=0.203) and Adiponectin (r=-0.201, p=0.158).
Conclusion: The adipo levels, which consider a pro-inflammatory marker for obesity enhance complications such as metabolic syndrome, insulin resistance, ischemic heart disease, and diabetic renal disease for women obese diabetes patients compared with non-obese diabetes patients.
Material & Methods: In this research, 54 female patients with type 2 diabetes and 36 non-diabetics participated, individuals from two groups, obese and non-obese, compared with apparently healthy control. The Adiponectin and Adiponectin receptor were measured by ELISA sandwich and Colorimetric methods were used for calculating fasting blood glucose. Blood samples were collected and drawn (5 ml) for each individual. For statistical analysis, SPSS 26.0 by ANOVA and Pearson's correlation coefficients were used.
Findings: Adiponectin and the Adiponectin receptor were measured, and the values of both were decreased in patients with type 2 diabetes who have the highest FBG, and also decreased for obese females, which have the highest BMI, where the positive significant values were observed when correlated body mass index (r=-0.57, p=0.001), and fasting blood glucose (r=0.291, p=0.0.06), while a negative correlated observed between Adiponectin receptor (r=-0.59, p=0.203) and Adiponectin (r=-0.201, p=0.158).
Conclusion: The adipo levels, which consider a pro-inflammatory marker for obesity enhance complications such as metabolic syndrome, insulin resistance, ischemic heart disease, and diabetic renal disease for women obese diabetes patients compared with non-obese diabetes patients.
Keywords:
References
1. Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. Cell. 2022;185(3):419-46. [Link] [DOI:10.1016/j.cell.2021.12.016]
2. Zhang Z, Du J, Shi H, Wang S, Yan Y, Xu Q, et al. Adiponectin suppresses tumor growth of nasopharyngeal carcinoma through activating AMPK signaling pathway. J Transl Med. 2022;20:89. [Link] [DOI:10.1186/s12967-022-03283-0]
3. Natalucci V, Virgili E, Calcagnoli F, Valli G, Agostini D, Zeppa SD, et al. Cancer related anemia: an integrated multitarget approach and lifestyle interventions. Nutrients. 2021;13(2):482. [Link] [DOI:10.3390/nu13020482]
4. Lu M, Tang Q, Olefsky JM, Mellon PL, Webster NJ. Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in LβT2 gonadotropes. Mol Endocrinol. 2008;22(3):760-71. [Link] [DOI:10.1210/me.2007-0330]
5. Abou-Samra M, Selvais CM, Dubuisson N, Brichard SM. Adiponectin and its mimics on skeletal muscle: insulin sensitizers, fat burners, exercise mimickers, muscling pills … or everything together?. Int J Mol Sci. 2020;21(7):2620. [Link] [DOI:10.3390/ijms21072620]
6. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes. 2008;32 Suppl 7:S13-8. [Link] [DOI:10.1038/ijo.2008.233]
7. Gonzalez LL, Garrie K, Turner MD. Type 2 diabetes-an autoinflammatory disease driven by metabolic stress. Biochim Biophys Acta Mol Basis Dis. 2018;1864(11):3805-23. [Link] [DOI:10.1016/j.bbadis.2018.08.034]
8. Choi SH, Hong ES, Lim S. Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol (Lausanne). 2013;4:97. [Link] [DOI:10.3389/fendo.2013.00097]
9. Rega-Kaun G, Kaun C, Wojta J. More than a simple storage organ: adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost. 2013;110(4):641-50. [Link] [DOI:10.1160/TH13-03-0212]
10. Lindber S, Mogelvang R, Pedersen SH, Bjerre M, Frystyk J, Flyvbjerg A, et al. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol. 2013;111(8):1139-45. [Link] [DOI:10.1016/j.amjcard.2012.12.043]
11. Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009;4(1):44-9. [Link] [DOI:10.1111/j.1559-4572.2008.00030.x]
12. Al-Ameri AA, AM AL-Mashhedy L. The Association between Lipocalin 2 and obesity for diabetic Female Type II. Nveo-Nat Volatiles Essential Oils J. 2021;8805-14. [Link]
13. Almubarak F. The association between known risk factors for type 2 diabetes, and the body mass index of diabetic adults [dissertation]. University of Arkansas; 2016 [Link]
14. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459-69. [Link] [DOI:10.1007/s00125-003-1074-z]
15. Park KG, Park KS, Kim MJ, Kim HS, Suh YS, Ahn JD, et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract. 2004;63(2):135-42. [Link] [DOI:10.1016/j.diabres.2003.09.010]
16. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699-713. [Link] [DOI:10.2337/diabetes.47.5.699]
17. Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CD, Nijpels, G, et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the hoorn study. Diabetes care. 2006;29(11):2498-503. [Link] [DOI:10.2337/dc06-0952]